ROCKVILLE, Md., Sept. 25, 2015 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that preliminary clinical data from ongoing Phase I studies of its anti-cancer compounds, Supinoxin™ and RX-3117, will be presented on Sunday, September 27, 2015 in two poster presentations at the joint 18th ECCO – 40th ESMO European Cancer Congress 2015 in Vienna, Austria.
Poster Title: Single Agent Supinoxin Targeting Phosphorylated p-68 Preliminary Phase I Data
Poster #: P155
Abstract #: 344
Session Date/Time: Sunday, September 27, 2015 4:45 p.m. – 6:45 p.m. CET
Author(s): Drs. W.L. Gluck and S.G. Eckhardt and M. Gutierrez
Poster Title: Preliminary Phase I Data of Single Agent RX-3117, an Oral Antimetabolite Nucleoside
Poster #: P156
Abstract #: 345
Session Date/Time: Sunday, September 27, 2015 4:45 p.m. – 6:45 p.m. CET
Author(s): Dr. D. Rasco
The ECCO-ESMO European Cancer Congress is a biennial congress focused on improving the prevention, diagnosis, treatment and care of cancer patients.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals Inc. (NYSE MKT:RNN) is a clinical stage biopharmaceutical company dedicated to developing novel, best-in-class therapeutics for the treatment of cancer. The Company’s mission is to improve the lives of cancer patients by developing next generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn’s product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Pre-clinical studies show that certain of Rexahn’s product candidates may be effective against multiple types of cancer, drug resistant cancers, and difficult-to-treat cancers, and others may augment the effectiveness of current FDA-approved cancer treatments. The Company has a broad oncology pipeline that includes three anti-cancer compounds currently in clinical development: Supinoxin™, RX-3117, and Archexin®, and a novel nanopolymer-based drug delivery platform technology that may increase the bio-availability of FDA-approved chemotherapies. For more information about the Company and its oncology programs, please visit www.rexahn.com.
Help employers find you! Check out all the jobs and post your resume.
Poster Title: Single Agent Supinoxin Targeting Phosphorylated p-68 Preliminary Phase I Data
Poster #: P155
Abstract #: 344
Session Date/Time: Sunday, September 27, 2015 4:45 p.m. – 6:45 p.m. CET
Author(s): Drs. W.L. Gluck and S.G. Eckhardt and M. Gutierrez
Poster Title: Preliminary Phase I Data of Single Agent RX-3117, an Oral Antimetabolite Nucleoside
Poster #: P156
Abstract #: 345
Session Date/Time: Sunday, September 27, 2015 4:45 p.m. – 6:45 p.m. CET
Author(s): Dr. D. Rasco
The ECCO-ESMO European Cancer Congress is a biennial congress focused on improving the prevention, diagnosis, treatment and care of cancer patients.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals Inc. (NYSE MKT:RNN) is a clinical stage biopharmaceutical company dedicated to developing novel, best-in-class therapeutics for the treatment of cancer. The Company’s mission is to improve the lives of cancer patients by developing next generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn’s product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Pre-clinical studies show that certain of Rexahn’s product candidates may be effective against multiple types of cancer, drug resistant cancers, and difficult-to-treat cancers, and others may augment the effectiveness of current FDA-approved cancer treatments. The Company has a broad oncology pipeline that includes three anti-cancer compounds currently in clinical development: Supinoxin™, RX-3117, and Archexin®, and a novel nanopolymer-based drug delivery platform technology that may increase the bio-availability of FDA-approved chemotherapies. For more information about the Company and its oncology programs, please visit www.rexahn.com.
Help employers find you! Check out all the jobs and post your resume.
